KUKJEON PHARMACEUTICAL Co., Ltd (KOSDAQ: 307750)
South Korea
· Delayed Price · Currency is KRW 3,580.00
-20.00 (-0.56%)
Dec 20, 2024, 9:15 AM KST
KUKJEON PHARMACEUTICAL Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Operating Revenue | 134,441 | 121,998 | 103,711 | 85,354 |
| Other Revenue | - | - | - | -0 |
| Revenue | 134,441 | 121,998 | 103,711 | 85,354 |
| Revenue Growth (YoY) | 15.22% | 17.63% | 21.51% | - |
| Cost of Revenue | 111,949 | 96,721 | 84,195 | 67,409 |
| Gross Profit | 22,492 | 25,277 | 19,515 | 17,946 |
| Selling, General & Admin | 14,675 | 12,817 | 11,451 | 8,699 |
| Research & Development | 4,434 | 4,821 | 3,981 | 2,651 |
| Operating Expenses | 20,537 | 18,768 | 16,027 | 11,836 |
| Operating Income | 1,955 | 6,509 | 3,488 | 6,109 |
| Interest Expense | -8,002 | -5,735 | -1,802 | -284.47 |
| Interest & Investment Income | 960.79 | 1,591 | 1,037 | 208.91 |
| Earnings From Equity Investments | -50.44 | 1.15 | 301.09 | - |
| Currency Exchange Gain (Loss) | 103.64 | -253.67 | -1,215 | -869.65 |
| Other Non Operating Income (Expenses) | 9,317 | -391.28 | 9,279 | 196.4 |
| EBT Excluding Unusual Items | 4,284 | 1,722 | 11,089 | 5,360 |
| Gain (Loss) on Sale of Investments | 1,272 | 16.28 | 67.84 | -275.98 |
| Gain (Loss) on Sale of Assets | -8.36 | - | -69.18 | -0 |
| Pretax Income | 4,342 | 1,738 | 11,088 | 5,084 |
| Income Tax Expense | -1,293 | -2,954 | 2,210 | 1,046 |
| Earnings From Continuing Operations | 5,636 | 4,692 | 8,877 | 4,038 |
| Minority Interest in Earnings | 956 | 132 | 70.7 | - |
| Net Income | 6,592 | 4,824 | 8,948 | 4,038 |
| Net Income to Common | 6,592 | 4,824 | 8,948 | 4,038 |
| Net Income Growth | -30.58% | -46.09% | 121.59% | - |
| Shares Outstanding (Basic) | 49 | 49 | 49 | 44 |
| Shares Outstanding (Diluted) | 49 | 49 | 51 | 44 |
| Shares Change (YoY) | -4.23% | -4.23% | 16.16% | - |
| EPS (Basic) | 134.33 | 98.31 | 182.35 | 91.54 |
| EPS (Diluted) | 134.02 | 98.00 | 11.35 | 91.00 |
| EPS Growth | 507.99% | 763.36% | -87.53% | - |
| Free Cash Flow | 3,086 | -44,269 | -29,304 | -7,367 |
| Free Cash Flow Per Share | 62.89 | -902.17 | -571.94 | -167.01 |
| Dividend Per Share | 10.000 | 10.000 | - | - |
| Gross Margin | 16.73% | 20.72% | 18.82% | 21.02% |
| Operating Margin | 1.45% | 5.34% | 3.36% | 7.16% |
| Profit Margin | 4.90% | 3.95% | 8.63% | 4.73% |
| Free Cash Flow Margin | 2.30% | -36.29% | -28.26% | -8.63% |
| EBITDA | 6,851 | 9,643 | 4,932 | 7,215 |
| EBITDA Margin | 5.10% | 7.90% | 4.76% | 8.45% |
| D&A For EBITDA | 4,896 | 3,134 | 1,444 | 1,106 |
| EBIT | 1,955 | 6,509 | 3,488 | 6,109 |
| EBIT Margin | 1.45% | 5.34% | 3.36% | 7.16% |
| Effective Tax Rate | - | - | 19.94% | 20.58% |
Source: S&P Capital IQ. Standard template. Financial Sources.